Pharmaceuticals, Biotechnology and Life Sciences
HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new…
F4 Pharma, a clinical-stage biopharmaceutical company developing FX06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, has included the first patient with severe COVID-19 in a study named “FX-COVID”, to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.
Pfizer’s and Biontech’s vaccine candidate for COVID-19 has met all the study’s primary efficacy endpoints.
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
Novartis will present 48 abstracts at the upcoming MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, September 11–13, 2020. The breadth of data being presented highlights the strength and promise of the company’s MS portfolio to improve the lives of patients across the MS spectrum.
Gyroscope doses first patient in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene.
The FDA approved an expanded indication of ViiV Healthcare’s Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 with no history of treatment failure or resistance to Dovato’s components.
Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.